BioRxive

https://biorxive.org/

RESEARCH ARTICLE

Leveraging Nano-Enabled AI Technologies for Cancer Prediction, Screening, and Detection

S. Archie[1], Harrison[2]

[1] Massachusetts Institute of Technology

[2] Adelphi University

ARTICLE INFO

Received: Jan 01, 2025
Accepted: Jan 12, 2025

Keywords
Cancer detection, Artificial Intelligence, Machine Learning, Deep Learning, Nanotechnology, Two-dimensional materials, Cancer biomarkers, Biosensors.

***Corresponding Author:**
Harrison26@gmail.com

ABSTRACT

Studies have recognized cancer as both a diverse and complex medical condition with multiple distinct characteristics. The correct early detection coupled with accurate diagnosis plays an essential role in executing clinical management techniques and it benefits survival rates. Healthcare benefits from the introduction of Artificial Intelligence (AI) alongside Machine Learning (ML) and Deep Learning (DL) which allows better cancer prediction capabilities. These statistical approaches process extensive data collections to reveal obscure systems that human beings have trouble identifying. The development of prediction models has been facilitated through AI algorithms where support vector machines (SVMs) and convolutional neural networks (CNNs) and artificial neural networks (ANNs) provide valuable enhancement to clinical decision processes in cancer research. This work studies how AI technology merges with developing nanotechnology by analyzing systems which combine AI principles with nanomaterial characteristics to detect cancer early then screen and treat cancer effectively. Our analysis explores recent developments in two-dimensional (2D) materials combined with smart sensors for cancer biomarker detection to establish diagnostic tools that bring accurate results through portable and affordable systems for clinical application. Cancer management is expected to experience a transformative change through these new innovations which support precise personalized treatment approaches. Widespread clinical use of these systems requires additional research because current technical limitations must be addressed in order to establish robust reliability.

I. INTRODUCTION

Cancer continues to be one of the most significant global health challenges, contributing to millions of deaths annually. The World Health Organization (WHO) reports that in 2018 alone, cancer was responsible for 9.6 million deaths, making it the second leading cause of death worldwide. This staggering statistic underscores the critical need for early detection, effective treatment strategies, and improved diagnostic techniques. Despite advances in medical technologies, many cancers are diagnosed at advanced stages, where treatment options become limited and prognosis less favorable [1]. Traditional diagnostic methods such as physical examinations, biopsies, and blood tests often fall short in their ability to detect cancers at early, asymptomatic stages. These methods also suffer from limitations in terms of sensitivity and specificity, leading to false positives and negatives. Consequently, the medical community is actively seeking novel approaches to enhance cancer detection and treatment. One of the most promising innovations in cancer research is the integration of artificial intelligence (AI) with nanotechnology, particularly in the realm of cancer prediction, screening, and detection. AI technologies, especially Machine Learning (ML) and Deep Learning (DL), have the potential to significantly improve diagnostic accuracy by processing and analyzing vast amounts of data [2]. ML algorithms, for example, can sift through complex datasets to identify patterns that may be invisible to human observers. These patterns can include subtle changes in tissue structure or biomarkers that signal the presence of cancer at an early stage. AI can enhance diagnostic imaging, making it more efficient and accurate. DL, a subset of ML, takes this further by simulating the way the human brain processes information, allowing for more advanced tasks such as image recognition and automated decision-making [3].

In parallel, nanotechnology has revolutionized the development of biosensors that can detect cancer biomarkers with unprecedented sensitivity. Nanomaterials, such as two-dimensional (2D) materials like graphene and Menes, offer unique advantages in biosensing applications. These materials possess extraordinary properties, including a high surface-area-to-volume ratio, excellent conductivity, and the ability to modify their chemical properties. For instance, graphene, a 2D material composed of a single layer of carbon atoms, is known for its high electron mobility and ability to functionalize easily with various biomolecules. This makes it an ideal candidate for creating highly sensitive biosensors for cancer biomarker detection. Menes, another class of 2D materials, are known for their high electrical conductivity and biocompatibility, making them suitable for applications in both diagnostics and drug delivery systems [4].

The integration of AI with nanomaterial-based biosensors allows for the development of diagnostic systems that are not only highly sensitive but also highly specific. These systems can detect biomarkers associated with various types of cancer, including lung, breast, colorectal, and prostate cancer, at very low concentrations, making early detection more feasible. AI algorithms can further enhance these biosensors by analyzing the data they generate, identifying patterns and correlations that could lead to more accurate diagnoses. This combination of AI and nanotechnology creates a feedback loop where data collected from sensors are processed by AI models to make predictions and provide real-time insights, thus facilitating faster and more accurate diagnoses [5].

Moreover, the use of 2D materials in the development of portable, cost-effective diagnostic tools is a significant step forward in making cancer detection more accessible. Traditional diagnostic methods often require expensive equipment and specialized medical expertise, which limits their availability, especially in low-resource settings. In contrast, nano-enabled biosensors, particularly those based on 2D materials, offer the potential to create portable, affordable diagnostic devices that can be used outside of clinical settings, enabling regular monitoring of health conditions. These sensors can be integrated into wearable devices, providing continuous, real-time monitoring of biomarkers, which is crucial for early detection and personalized treatment strategies [6].

The convergence of AI and nanotechnology has the potential to redefine cancer diagnosis and treatment. AI's ability to analyze large datasets and make accurate predictions, combined with the sensitivity of nanomaterial-based sensors, creates a powerful tool for cancer detection. While the technology is still in its developmental stages, the progress made so far is promising, with several research groups demonstrating the successful application of AI-enabled nanomaterial biosensors for cancer detection. However, more research and validation are needed before these systems can be widely implemented in clinical practice. Regulatory approval, long-term studies, and the integration of these technologies into routine healthcare work. Lows will be crucial for their widespread adoption. Nevertheless, the potential for AI and nanotechnology to transform the landscape of cancer diagnosis is immense, offering hope for earlier detection, more accurate prognosis, and ultimately, improved patient outcomes.

I. Research Findings

A. Role of Artificial Intelligence in Cancer Diagnosis

Recent medical practice depends on artificial intelligence to bring major improvements into cancer diagnosis and treatment processes. Large datasets processing ability of AI systems especially machine learning (ML) and deep learning (DL) makes these systems highly valuable in cancer detection and diagnosis [7].

i. Machine Learning and Deep Learning in Healthcare

Machine learning functions as one component of artificial intelligence which enables computers to learn automatically from pre-processed data. As a subcategory of machine learning deep learning establishes multi-layered neural networks which identify intricate patterns. Through processing clinical data combined with imaging results and genomic information these AI techniques assist healthcare providers for more precise cancer diagnoses. ML algorithms analyze pathology slides to detect cancerous cells and predict the clinical chances of cancer progression using genetic data from inherited mutations [8].

ii. Enhancing Diagnostic Imaging with AI

AI advances medical imaging substantially as it changes practice in both radiology alongside pathology departments. Advanced algorithms developed with deep learning technology can identify tumors in X-ray and MRI and CT scan images. Modern systems possess the capability to identify elusive patterns together with indications of irregularities which standard human vision may overlook. Through advanced diagnostics enabled by AI medical staff achieve improved image interpretation accuracy while lowering both diagnostic timing and expense [9].

a. Predictive Models for Early Detection:

The predictive capabilities of artificial intelligence demonstrate great promise for discovering cancer at its earliest stages. Health data analysis through AI permits tracking of possible cancer indicators across time leading to cancer predefection before physical illness onset. Medical providers can discover cancer at earlier stages through predictive modelling which highly improves the probability of effective treatment results. AI predictive tools evaluate patient data to assess risk factors together with biomarkers which subsequently performs proactive screenings while being essential in creating personalized cancer treatments [10].

b. Cancer Diagnosis and Therapy

Nanotechnology exists as a field that conducts atomic and molecular manipulation of materials featuring sizes between one and one hundred nanometers. The ability to work at the molecular scale makes nanotechnology essential for cancer diagnosis and therapy techniques because it allows precise biological system interactions. The use of nanomaterials especially two-dimensional materials such as graphene and Menes enables advanced cancer detection when used as sensitive biomarker-detecting sensors.

iii. Cancer Biosensors

Nanomaterials serve as optimal candidates for cancer biosensor development because they exhibit simultaneous properties of minute dimensions, broad exposed surfaces and specialized biological binding capabilities [11]. The binding of cancer biomarkers to materials like gold nanoparticles along with quantum dots and carbon-based nanomaterials including graphene enables functionalization. After binding to cancer biomarkers these nanomaterials provide exceptional precision enabling cancer detection at extremely early stages. Low levels of tumor markers can be detected through Gold, nanoparticle-based biosensor methods which enable blood-based cancer monitoring without invasive procedures.

B. Graphene and Menes: The Power of 2D Materials

Graphene stands as a leading nanomaterial for cancer diagnosis because its hexagonal lattice carbon arrangement shows excellent mechanical electrical and optical capabilities. The excellent blend of surface area and conductivity properties transforms graphene into an ideal component for biosensing applications due to its ability to support antibody and biomarker binding. The family of two-dimensional materials known as Menes has received increasing interest because of their high sensitivity along with good biocompatibility which enables their use in both cancer diagnosis and drug delivery [12].

i. Convergence of AI and Nanotechnology for Cancer Detection

The convergence of artificial intelligence technology with nano systems creates promising prospects for advanced cancer detection methods. Medical professionals can reach dramatic accuracy enhancements with speed and personalized diagnostic capabilities by using the combined power of AI and nanotechnology in cancer detection.

a. Synergy:

Nanotechnology synergizes with AI by leveraging their distinct strengths together. To achieve elevated sensitivity for cancer biomarker detection nanomaterials, work hand in hand with Artificial Intelligence which processes and interprets sensor data quantities. The analysis of nanomaterial-based biosensor data by AI algorithms reveals invisible relationships through advanced algorithms to achieve superior diagnosis results along with patient-tailored treatment.

b. Development of Nano-Enabled AI-Based Systems:

The workforce and clinical trials should represent all populations. Cultural competence among providers ensures better patient outcomes and builds trust in underserved communities.

c. Ethical Patient Care:

Scientists develop integrated systems today by integrating AI technologies into nano-enabled biosensors to enable real-time cancer diagnosis. The detection of biomarkers using nanomaterials precedes artificial intelligence algorithm-based data analysis in these systems. Such systems demonstrate potential as portable point-of-care diagnostic tools that healthcare services can implement in hospitals and remote clinics alike [13].

ii. Advantages of the Converged Technology

Combining artificial intelligence with nanotechnology systems generates enhanced diagnostic precision alongside timelier disease detection as well as precise medical treatments adapted to individual patient needs [14]. Early cancer detection enabled by Nano enabled AI systems occurs even before patients develop symptoms because this allows dramatic improvements in survival rates. Doctors can develop individualized treatment approaches for each patient's cancer via strategic combinations of AI automation with nanomaterial-based targeted therapies which focus directly on the specific DNA attributes and protein expression profiles unique to the patient's cancer cells.

iii. Emerging Trends and Future Prospects

Scientists actively investigate exciting joint research of cancer diagnosis between artificial intelligence systems and nanotechnology that promises substantial prospects for the future. Advancements in cancer detection and treatment analysis will become increasingly significant due to ongoing development within both AI and nanotechnology frameworks [15].

C. The Role of AI in Personalized Cancer Treatment

Through analyzing genetic information and tumor markers and treatment response data AI provides essential support to personalized cancer treatments. By combining artificial intelligence with nanotechnology doctors achieve early cancer detection along with the creation of targeted treatment solutions targeting cancer cells without damaging healthy tissue.

i. Future of AI-Nanotech Systems in Clinical Settings

AI-based diagnostic systems supported by nanotechnology will appear throughout clinical areas in the near future. Modern nano-enabled artificial intelligence diagnostic systems have the potential to improve cancer treatment delivery with their fast and precise diagnosis ability and individualized treatment design capacity [16]. Widest acceptance of these technologies depends on resolving scalability issues and obtaining regulatory approvals along with managing costs.

ii. Challenges and Limitations

AI and nanotechnology integration in clinical practice requires resolution of multiple obstacles to reach full implementation. Current efforts to create nano-enabled AI systems face active technical barriers even though major development breakthroughs have happened. Present AI diagnostic systems encounter difficulties with medical data quality alongside missing standardization which leads to reduced diagnostic precision. Large-scale manufacturing of nanomaterial-based sensors needs improved research to address production scale-up problems and stability and reliability issues.

D. Ethical and Regulatory Considerations

The development and deployment of AI and nanotechnology in healthcare raise important ethical and regulatory issues [17]. The processing of important patient data requires the use of AI in medical diagnostics to maintain effective security protections and maintain privacy. Healthcare approval of nano-enabled AI systems for clinical use undergoes an extensive regulatory process that demands prolonged testing and validation phases.

i. Cost and Accessibility Barriers

Widely spread adoption of AI and nanotechnology for cancer diagnosis faces major challenges linked to expense. The manufacturing expenses for both nanomaterials and AI systems create barriers for wider technological access across low-resource areas. Providing affordability and widespread access to these technologies for all cancer patients represents an essential challenge for the upcoming years [18].

ii. Advances in AI-Driven Cancer Screening Tools

The development of AI technologies continues actively while their applications for screening tools grow broader. Revolutionary innovations develop new options for early cancer diagnosis which combine low invasiveness with minimal cost and precise detection abilities.

E. AI-Powered Screening Devices

AI algorithms integrated with imaging devices such as mammograms, CT scans, and ultrasounds are revolutionizing the way clinicians screen for cancer. These AI-powered devices are designed to analyze images for patterns indicative of tumors or pre-cancerous conditions, reducing the possibility of human error [19].

i. AI in Liquid Biopsy for Cancer Detection

The diagnostic method of liquid biopsy analyses tissue-related molecules within blood and urine cells to detect cancer predisposition. Lawrence Swanick shows how artificial intelligence optimizes liquid biopsy accuracy by detecting hard-to-pinpoint biomarkers when they exist at traceable levels.

F. Real-World Applications and Clinical Trials

Healthcare industries are undergoing a transformation through the combination of artificial intelligence with nanotechnology which brings improvements to cancer diagnosis and therapeutic approaches [20]. These technologies demonstrate significant pre-clinical potential which now starts to meet its first real-world medical usages. Active initiatives to translate laboratory discoveries into clinical practices are underway through the combined efforts of researchers and clinicians and biotech companies. The implementation of AI diagnostic systems based on nanomaterials needs real-world testing to prove their effectiveness while making sure they fit properly within healthcare operational structures. The medical implementation of AI alongside nanotechnology shows particular importance for cancer treatment strategies because early recognition and precise assessments drive better patient results. The progressive clinical trials demonstrate how these technologies evolve into clinical practice while revealing their transformative power across multiple levels of cancer care [21].

a. Case Studies in Cancer Detection Using Nano-AI Systems:

Multiple real-life examples prove that artificial intelligence combined with nanotechnology methods successfully identify cancer early stages during screenings. Real-world case studies delve into how both technologies accomplish diagnostic duties in medical practice and demonstrate their superior performance over traditional diagnostic procedures for early cancer detection. AI-powered imaging utilizing nanomaterials served as the subject of a recent study which evaluated their capacity for early breast cancer detection. echotomography examination enabled AI through training using multiple thousands of breast scan images to identify hidden tumors which traditional human eyes cannot view [22]. The implementation of nanomaterials containing functionalized gold nanoparticles enhanced both imaging resolution and cancerous lesion localization precision. The AI system's capability to assess high-definition pictures together with nanotechnology improved detection rates substantially beyond what traditional mammography offered.

b. Ongoing Clinical Trials and Pilot Programs:

Several ongoing clinical studies function as essential tools for developing correct methodologies along with ensuring the reliability of AI and nanotechnology-based cancer screening solutions and therapy systems. Traditional clinical tests function to acquire essential data about how these technologies work together for safety evaluation and effectiveness assessment while measuring their operational value which ensures medical organizations employ them. Active clinical trials assess different applications of AI combined with nanotechnology throughout cancer therapy at present. Research teams continue validating a testing program that involves AI detection algorithms working in tandem with imaging systems using gold nanoparticles for pancreatic cancer identification. Research teams explore how integrative technologies perform in spotting pancreatic tumors during early stages because detecting cancer at earlier stages enables improved patient survival outcomes. Researchers evaluate the gold nanoparticles both for their safety profile and their bio-compatibility properties to guarantee they will not trigger undesirable reactions in human bodies [23].

i. Predictions for the Next Decade

a. Enhance Reporting and Compliance:

Future developments in medical cancer care appear promising for both artificial intelligence applications and nanoscale research. We will likely experience major transformations in cancer diagnostics and treatments as these technologies continue to enhance their speed as well as precision and accessibility. AI-based nano sensors demonstrate exceptional potential for cancer screening because they can instantly recognize biomarkers from bodily fluids which include blood and either saliva or urine. Engineered nano sensors created from fundamental molecular components will deliver precise detection of cancer biomarkers thereby improving both identification speed and early detection quality [24].

b. Emerging Technologies and Their Impact on Cancer Care:

AI technologies and nanotechnology keep progressing while new breakthroughs in technology will expand the capabilities of cancer treatment. The future of biological data analysis depends on quantum computing capabilities which promise dramatic improvements. Quantum computing shows fast processing of large data amounts at exponential speeds than modern systems which enables AI cancer detection algorithms to find early-stage cancer cells more accurately. Nanotechnology's ongoing development of advanced nanorobots named "nanobots" targets major improvements for cancer treatments. Scientists might create tiny robotic systems to guide through living tissues since these systems could concentrate therapy at cancer cells without touching healthy biological structures [9]. The precise delivery systems would minimize the typical damaging repercussions of traditional chemotherapy and radiation treatments which would expand opportunities for safer and better cancer treatments. As part of their diagnostic capabilities nanobots have embedded tools enabling third-level analysis to detect cancer cells which feed the data to AI-powered healthcare systems for medical professional use. The unified diagnostic and therapeutic capacity of this system presents an opportunity to exchange cancer treatments with more successful personalized and minimally invasive procedures.

II. Conclusion

Artificial Intelligence combined with nanotechnology shows substantial potential to transform the way we manage cancer. The landscape of oncology will experience transformation through technologies which combine AI with nanotechnology to boost diagnostic accuracy and enable early detection and provide individualized treatment choices. Nano sensors and nanorobots driven by artificial intelligence capabilities will perform rapid non-invasive disease screenings and selective medical interventions alongside emerging quantum computing systems and refined nanorobotic solutions. Medical innovations face continuing obstacles which prevent their widespread distribution to diverse populations between clinical confirmation and regulatory clearances. Although challenges exist these hurdles should not impede the goal of developing a cancer-free future backed by early identification and tailored therapy possibilities. The convergence of AI and nanotechnology research shows promise to revolutionize cancer detection capabilities as well as treatment and prevention methods so millions of people worldwide will benefit from improved outcomes.

III. References

1. Thato, P., Choudhary, R., Shalane, A., Qureshi, H. A., & Kumar, S. (2023). Natural Language Processing (NLP) in the Extraction of Clinical Information from Electronic Health Records (EHRs) for Cancer Prognosis. International Journal, 10(4), 2676-2694.

2. Gondal, M. N., Shah, S. U. R., Chinnaiyan, A. M., & Cieslik, M. (2024). A systematic overview of single-cell transcriptomics databases, their use cases, and limitations. Frontiers in Bioinformatics, 4, 1417428.

3. Gondal, M. N., & Chaudhary, S. U. (2021). Navigating multi-scale cancer systems biology towards model-driven clinical oncology and its applications in personalized therapeutics. Frontiers in Oncology, 11, 712505.

4. Gondal, M. N., Butt, R. N., Shah, O. S., Sultan, M. U., Mustafa, G., Nasir, Z., ... & Chaudhary, S. U. (2021). A personalized therapeutics approach using an in silico drosophila patient model reveals optimal chemo-and targeted therapy combinations for colorectal cancer. Frontiers in Oncology, 11, 692592.

5. Khurshid, G., Abbassi, A. Z., Khalid, M. F., Gondal, M. N., Naqvi, T. A., Shah, M. M., ... & Ahmad, R. (2020). A cyanobacterial photorespiratory bypass model to enhance photosynthesis by rerouting photorespiratory pathway in C3 plants. Scientific Reports, 10(1), 20879.

6. Gondal, M. N., Sultan, M. U., Arif, A., Rehman, A., Awan, H. A., & Arshad, Z. (2021). & Chaudhary, SU (2021). TISON: a next-generation multi-scale modeling theatre for in silico systems oncology. BioRxiv, 5.

7. Gondal, M. N., Butt, R. N., Shah, O. S., Sultan, M. U., Mustafa, G., Nasir, Z., ... & Chaudhary, S. U. (2021). A personalized therapeutics approach using an in silico drosophila patient model reveals optimal chemo-and targeted therapy combinations for colorectal cancer. Frontiers in Oncology, 11, 692592.

8. Gondal, M. N., Mannan, R., Bao, Y., Hu, J., Cieslik, M., & Chinnaiyan, A. M. (2024). Pan-tissue master regulator inference reveals mechanisms of MHC alterations in cancers. Cancer Research, 84(6_Supplement), 860-860.

9. Bao, Y., Qiao, Y., Choi, J. E., Zhang, Y., Mannan, R., Cheng, C., ... & Chinnaiyan, A. M. (2023). Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy. Proceedings of the National Academy of Sciences, 120(49), e2314416120.

10. Borker, P., Bao, Y., Qiao, Y., Chinnaiyan, A., Choi, J. E., Zhang, Y., ... & Zou, W. (2024). Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy. Cancer Research, 84(6_Supplement), 7479-7479.

11. Choi, J. E., Qiao, Y., Kryczek, I., Yu, J., Gurkan, J., Bao, Y., ... & Chinnaiyan, A. M. (2024). PIKfyve, expressed by CD11c-positive cells, controls tumor immunity. Nature Communications, 15(1), 5487.

12. Gondal, M. N., Sultan, M. U., Arif, A., Rehman, A., Awan, H. A., Arshad, Z., ... & Chaudhary, S. U. (2021). TISON: a next-generation multi-scale modeling theatre for in silico systems oncology. BioRxiv, 2021-05.

13. Gondal, M. N., Butt, R. N., Shah, O. S., Sultan, M. U., Mustafa, G., & Nasir, Z. & Chaudhary, SU (2022). A Personalized Therapeutics Approach Using an In Silico. Combinatorial Approaches for Cancer Treatment: from Basic to Translational Research.

14. Gondal, M. N., Butt, R. N., Shah, O. S., Nasir, Z., Hussain, R., Khawar, H., ... & Chaudhary, S. U. (2020). In silico Drosophila Patient Model Reveals Optimal Combinatorial Therapies for Colorectal Cancer. bioRxiv, 2020-08.

15. Gondal, M. N. (2024). Assessing Bias in Gene Expression Omnibus (GEO) Datasets. bioRxiv, 2024-11.

16. Choi, J. E., Qiao, Y., Kryczek, I., Yu, J., Gurkan, J., Bao, Y., ... & Chinnaiyan, A. M. (2024). PIKfyve controls dendritic cell function and tumor immunity. bioRxiv.

17. Gondal, M. N., & Chaudhary, S. U. (2021). Navigating Multi-scale Cancer Systems Biology towards Model-driven Personalized Therapeutics. bioRxiv, 2021-05.

18. Gondal, M. N., & Farooqi, H. M. U. (2025). Single-Cell Transcriptomic Approaches for

Decoding Non-Coding RNA Mechanisms in Colorectal Cancer. Non-Coding RNA, 11(2), 24.

19. Borker, P., Bao, Y., Qiao, Y., Chinnaiyan, A., Choi, J. E., Zhang, Y., ... & Zou, W. (2024). Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy. Cancer Research, 84(6_Supplement), 7479-7479.

20. Butt, R. N., Amina, B., Sultan, M. U., Tanveer, Z. B., Hussain, R., Akbar, R., ... & Chaudhary, S. U. (2022). CanSeer: A Method for Development and Clinical Translation of Personalized Cancer Therapeutics. bioRxiv, 2022-06.
21. Saeed, F., Shivani, A., Umar, M., Jahangir, Z., Tahir, A., & Shivani, S. (2025). Hepatocellular Carcinoma Prediction in HCV Patients using Machine Learning and Deep Learning Techniques. Journal Ilmiah Computer Science, 3(2), 120-134.
22. Kumar, S., Hasan, S. U., Shivani, A., Kumar, S., & Kumar, S. DEEP LEARNING APPROACHES TO MEDICAL IMAGE ANALYSIS: TRANSFORMING DIAGNOSTICS AND TREATMENT PLANNING.
23. Kumar, S., Shivani, A., Hasan, S. U., Kumar, S., Shamsi, F., & Hasan, S. Artificial Intelligence in Organ Transplantation: A Systematic Review of Current Advances, Challenges, and Future Directions.